89bio to participate in upcoming investor conferences

San francisco, may 06, 2025 (globe newswire) -- 89bio, inc. (the “company” or “89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the company's management will participate in the following investor conferences during the month of may:
ETNB Ratings Summary
ETNB Quant Ranking